FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912584937> ?p ?o ?g. }

• W2912584937 endingPage "79" @default.
• W2912584937 startingPage "73" @default.
• W2912584937 abstract "International guidelines recommend treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID), including those on opioid substitution therapy (OST). The pangenotypic combination of glecaprevir and pibrentasvir has shown high sustained virologic response at post-treatment Week 12 (SVR12) in clinical trials. Herein, we evaluate the safety and efficacy of glecaprevir/pibrentasvir in patients receiving OST.Pooled data from patients with HCV genotypes 1-6 who were treated with glecaprevir/pibrentasvir for 8, 12, or 16 weeks in eight Phase 2 and 3 trials were categorized by use of OST. Treatment completion, treatment adherence, SVR12, adverse events (AEs), and laboratory abnormalities were evaluated for patients receiving and not receiving OST.Among 2256 patients, 157 (7%) were receiving OST. Compared with patients not receiving OST, OST patients were younger (mean age, 46.8 vs 52.8 years), male (69% vs 54%), white (93% vs 80%), HCV treatment-naïve (86% vs 72%), had HCV genotype 3 (60% vs 26%), and had a history of depression or bipolar disorder (43% vs 19%). Most patients completed (OST: 98% [n/N = 154/157]; non-OST: 99% [n/N = 2070/2099]) and were adherent (received ≥90% of study drug doses) to glecaprevir/pibrentasvir treatment (OST: 98% [n/N = 121/123]; non-OST: 99% [n/N = 1884/1905] among patients with available data). In the intention-to-treat population, SVR12 rates in OST and non-OST patients were 96.2% (n/N = 151/157; 95% CI 93.2-99.2) and 97.9% (n/N = 2055/2099; 95% CI 97.3-98.5), respectively. For OST patients, reasons for nonresponse included virologic relapse (<1%; n = 1), premature study drug discontinuation (<1%; n = 1), and loss to follow-up (3%; n = 4). AEs occurring in ≥10% of OST patients were headache, fatigue, and nausea. Drug-related serious AEs, AEs leading to study drug discontinuation, and Grade 3 or higher laboratory abnormalities were infrequent in both groups (<1%). No HCV reinfections occurred through post-treatment Week 12.Glecaprevir/pibrentasvir is highly efficacious and well tolerated in HCV-infected patients receiving OST." @default.
• W2912584937 created "2019-02-21" @default.
• W2912584937 creator A5004579061 @default.
• W2912584937 creator A5013161111 @default.
• W2912584937 creator A5020475843 @default.
• W2912584937 creator A5025741164 @default.
• W2912584937 creator A5043306295 @default.
• W2912584937 creator A5045529959 @default.
• W2912584937 creator A5048297844 @default.
• W2912584937 creator A5052909853 @default.
• W2912584937 creator A5056578595 @default.
• W2912584937 creator A5058318375 @default.
• W2912584937 creator A5077021592 @default.
• W2912584937 creator A5089037721 @default.
• W2912584937 date "2019-04-01" @default.
• W2912584937 modified "2023-10-16" @default.
• W2912584937 title "Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy" @default.
• W2912584937 cites W171434351 @default.
• W2912584937 cites W1761216664 @default.
• W2912584937 cites W1903580466 @default.
• W2912584937 cites W2001458978 @default.
• W2912584937 cites W2006747389 @default.
• W2912584937 cites W2072257689 @default.
• W2912584937 cites W2142011497 @default.
• W2912584937 cites W2167150962 @default.
• W2912584937 cites W2185218296 @default.
• W2912584937 cites W2258490349 @default.
• W2912584937 cites W2274680380 @default.
• W2912584937 cites W2406118020 @default.
• W2912584937 cites W2481637770 @default.
• W2912584937 cites W2487282667 @default.
• W2912584937 cites W2518041763 @default.
• W2912584937 cites W2518485884 @default.
• W2912584937 cites W2581550425 @default.
• W2912584937 cites W2605284316 @default.
• W2912584937 cites W2620881498 @default.
• W2912584937 cites W2626989754 @default.
• W2912584937 cites W2728617459 @default.
• W2912584937 cites W2729748948 @default.
• W2912584937 cites W2746084941 @default.
• W2912584937 cites W2749707246 @default.
• W2912584937 cites W2756644889 @default.
• W2912584937 cites W2761085897 @default.
• W2912584937 cites W2762789262 @default.
• W2912584937 cites W2765348434 @default.
• W2912584937 cites W2782256918 @default.
• W2912584937 cites W2788216918 @default.
• W2912584937 cites W2793631939 @default.
• W2912584937 cites W2805345171 @default.
• W2912584937 cites W2889967332 @default.
• W2912584937 cites W2893294532 @default.
• W2912584937 doi "https://doi.org/10.1016/j.drugpo.2019.01.011" @default.
• W2912584937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30735896" @default.
• W2912584937 hasPublicationYear "2019" @default.
• W2912584937 type Work @default.
• W2912584937 sameAs 2912584937 @default.
• W2912584937 citedByCount "25" @default.
• W2912584937 countsByYear W29125849372018 @default.
• W2912584937 countsByYear W29125849372019 @default.
• W2912584937 countsByYear W29125849372020 @default.
• W2912584937 countsByYear W29125849372021 @default.
• W2912584937 countsByYear W29125849372022 @default.
• W2912584937 countsByYear W29125849372023 @default.
• W2912584937 crossrefType "journal-article" @default.
• W2912584937 hasAuthorship W2912584937A5004579061 @default.
• W2912584937 hasAuthorship W2912584937A5013161111 @default.
• W2912584937 hasAuthorship W2912584937A5020475843 @default.
• W2912584937 hasAuthorship W2912584937A5025741164 @default.
• W2912584937 hasAuthorship W2912584937A5043306295 @default.
• W2912584937 hasAuthorship W2912584937A5045529959 @default.
• W2912584937 hasAuthorship W2912584937A5048297844 @default.
• W2912584937 hasAuthorship W2912584937A5052909853 @default.
• W2912584937 hasAuthorship W2912584937A5056578595 @default.
• W2912584937 hasAuthorship W2912584937A5058318375 @default.
• W2912584937 hasAuthorship W2912584937A5077021592 @default.
• W2912584937 hasAuthorship W2912584937A5089037721 @default.
• W2912584937 hasBestOaLocation W29125849371 @default.
• W2912584937 hasConcept C126322002 @default.
• W2912584937 hasConcept C197934379 @default.
• W2912584937 hasConcept C203014093 @default.
• W2912584937 hasConcept C2522874641 @default.
• W2912584937 hasConcept C2776408679 @default.
• W2912584937 hasConcept C2776455275 @default.
• W2912584937 hasConcept C2908647359 @default.
• W2912584937 hasConcept C71924100 @default.
• W2912584937 hasConcept C90924648 @default.
• W2912584937 hasConcept C99454951 @default.
• W2912584937 hasConceptScore W2912584937C126322002 @default.
• W2912584937 hasConceptScore W2912584937C197934379 @default.
• W2912584937 hasConceptScore W2912584937C203014093 @default.
• W2912584937 hasConceptScore W2912584937C2522874641 @default.
• W2912584937 hasConceptScore W2912584937C2776408679 @default.
• W2912584937 hasConceptScore W2912584937C2776455275 @default.
• W2912584937 hasConceptScore W2912584937C2908647359 @default.
• W2912584937 hasConceptScore W2912584937C71924100 @default.
• W2912584937 hasConceptScore W2912584937C90924648 @default.
• W2912584937 hasConceptScore W2912584937C99454951 @default.
• W2912584937 hasFunder F4320309117 @default.

• next